Hualan Biological Engineering Inc. (SHE: 002007)

Market Cap	29.64B
Revenue (ttm)	4.92B
Net Income (ttm)	1.34B
Shares Out	1.83B
EPS (ttm)	0.73
PE Ratio	22.17
Forward PE	18.63
Dividend	0.30 (1.78%)
Ex-Dividend Date	n/a

Volume	9,767,767
Open	17.33
Previous Close	17.51
Day's Range	17.33 - 17.57
52-Week Range	13.72 - 22.30
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 29, 2025

About Hualan Biological Engineering

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes blood products, vaccines, and recombinant proteins in China and internationally. The company offers blood products under the Hualan brand comprising human albumin, intravenous human immunoglobulin, human immunoglobulin, tetanus human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, human prothrombin complex, human coagulation factor VIII, human fibrinogen, freeze-dried human fibrin glue for surgery, and hum...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 3,709
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2023, Hualan Biological Engineering's revenue was 5.34 billion, an increase of 18.26% compared to the previous year's 4.52 billion. Earnings were 1.48 billion, an increase of 37.66%.